Peptide Therapeutics Market (Product Type - Generic, and Branded; Application - Gastrointestinal Disorders, Neurological Disorders, Metabolic Disorders, Cancer, and Other Applications; Route of Administration - Parenteral, Oral, and Other Routes of Administration): Global Industry Analysis, Trends, Size, Share and Forecasts to 2030

A recent report published by Infinium Global Research on peptide therapeutics market provides in-depth analysis of segments and sub-segments in the global as well as regional peptide therapeutics market. The study also highlights the impact of drivers, restraints, and macro indicators on the global and regional peptide therapeutics market over the short term as well as long term. The report is a comprehensive presentation of trends, forecast and dollar values of global peptide therapeutics market.

Market Insight:

The global peptide therapeutics market was valued at approximately USD 45 billion in 2022 and is expected to reach nearly USD 103 billion in 2030, with a CAGR of around 10% during the forecast period 2023-2030.

Peptides are short chains of amino acids linked by peptide bonds that serve diverse functions within cells, such as signaling and combating infections. The potential usefulness of a peptide for therapeutic purposes is determined by its sequence, which may be based on naturally occurring peptides, structurally similar peptides, or novel sequences. The peptide therapeutics market is expected to experience substantial growth due to several factors, including the rising prevalence of metabolic disorders and cancer, increased investments in research and development of new drugs, and advancements in peptide therapeutic technologies. The World Health Organization (WHO) reports that chronic diseases like diabetes, cardiovascular diseases, and cancer are the primary causes of death and disability globally. Additionally, the growing number of cancer cases worldwide, coupled with technological advancements, is expected to generate opportunities for growth throughout the forecasted period.

Over the last few years, the global peptide therapeutics market has seen significant growth due to the increasing number of cancer patients and the rising prevalence of metabolic disorders. The market is expected to continue to expand as a result of growing research activities and the development of new peptide drugs. However, stringent regulatory requirements for drug approval may impede market growth. Despite this, the rising incidence of metabolic disorders worldwide is projected to create several opportunities for growth in the coming years. With the increasing demand for peptide therapeutics to address various health conditions, market players are focusing on developing innovative peptide-based drugs to meet the unmet medical needs of patients. Additionally, advancements in drug delivery systems and technologies are expected to provide lucrative opportunities for market growth in the near future.

Based on region the market is bifurcated into North America, Europe, Asia-Pacific, and the Rest of the World. North America holds the largest market share and is projected to maintain its dominance throughout the forecast period. This can be attributed to factors such as a growing awareness of peptide-based therapeutics, an increased need for diagnostics in cancer and other diseases, and a thriving biotechnology industry. Europe is the second-largest market globally, with prominent countries such as Germany, Spain, the Netherlands, and the UK. The market growth in this region is driven by the emergence of pharmaceutical and biotech firms, significant investment in healthcare startups, and government initiatives to develop cost-effective and safe drugs. Meanwhile, Asia-Pacific is expected to be the most lucrative market, with the highest compound annual growth rate (CAGR) in the upcoming years. The region's sophisticated healthcare infrastructure and a rising population of cancer patients, coupled with increasing incidences of metabolic disorders, are expected to fuel market growth in this region. As a result of the growing demand for peptide therapeutics, market players are increasing their investments in research and development, expanding their product portfolios, and collaborating with regional players to establish their presence in these markets.

Report Scope of the Peptide Therapeutics Market:

Segment Covered

The report on global peptide therapeutics market covers segments such as product type, application, and route of administration. On the basis of product type, the sub-markets include generic, and branded. On the basis of application, the sub-markets include gastrointestinal disorders, neurological disorders, metabolic disorders, cancer, and other applications. On the basis of route of administration, the sub-markets include parenteral, oral, and other routes of administration.

The report provides profiles of the companies in the market such as Teva Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Sanofi, Pfizer Inc., Novartis AG, GSK plc, F. Hoffmann-La Roche Ltd, Lilly, Bachem, Amgen Inc, and Others.

Report Highlights:

The report provides deep insights into demand forecasts, market trends, and micro and macro indicators. In addition, this report provides insights into the factors that are driving and restraining the growth in this market. Moreover, The IGR-Growth Matrix analysis given in the report brings an insight into the investment areas that existing or new market players can consider. The report provides insights into the market using analytical tools such as Porter's five forces analysis and DRO analysis of the peptide therapeutics market. Moreover, the study highlights current market trends and provides forecasts from 2023-2030. We also have highlighted future trends in the market that will affect the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight into the market share of the leading players.